<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="89118">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01994252</url>
  </required_header>
  <id_info>
    <org_study_id>RN00208414</org_study_id>
    <nct_id>NCT01994252</nct_id>
  </id_info>
  <brief_title>Resynchronization/Defibrillation for Ambulatory Heart Failure Trial in Patients With Permanent Atrial Fibrillation</brief_title>
  <acronym>RAFT-PermAF</acronym>
  <official_title>Resynchronization/Defibrillation for Ambulatory Heart Failure Trial in Patients With Permanent Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Ottawa Heart Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research  (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Ottawa Heart Institute</source>
  <oversight_info>
    <authority>Canada: Ethics Review Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Atrial fibrillation (AF) and heart failure (HF) are two common heart conditions that are
      encountered with an increase in death and suffering.  When both these two conditions occur
      in a patient, the patient's prognosis is poor with a reduced quality of life. These patients
      are frequently admitted to the hospital and have increased risk of death.  In these HF
      patients who are in AF all of the time, who would otherwise be a suitable candidate for an
      implantable defibrillator to prevent sudden cardiac death, whether adding pacing of both
      ventricles will reduce death and suffering.  Other studies have shown that adding pacing to
      both ventricles is of benefit in HF patients with mild to moderate symptoms and have a
      regular heart rhythm. The Investigators now want to explore if this therapy will benefit
      those patients with a permanent irregular heart rhythm (AF). The Investigators will also be
      assessing the cost effectiveness of this treatment strategy and the life quality for these
      patients. This study may have a dramatic impact on the way the Investigators manage these
      patients with atrial fibrillation and heart failure and may improve the outlook and well
      being of these patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Heart failure (HF) is increasing in prevalence and incidence, and is the most common reason
      for hospital admissions of patients over the age of 65. Therapy for HF has evolved over the
      last two decades. Cardiac resynchronization therapy (CRT) is a therapy that attempts to
      resynchronize the sequence of ventricular contraction in heart failure (HF) patients with
      left ventricular (LV) systolic dysfunction and ventricular dyssynchrony.  CRT is achieved by
      stimulating both RV and LV together, synchronized to right atrial excitation to achieve
      atrio-ventricular synchrony. Clinical trials have demonstrated that CRT improved survival
      and reduced HF hospitalization in mild to advanced HF patients. In addition, CRT reversed
      the remodeling process such that it was associated with a reduction of LV size, and an
      increase of LV ejection fraction (EF). This knowledge translated to a change in practice
      guidelines and the adoption of CRT into clinical practice benefitting many HF patients CRT
      is now an important state-of-the-art therapy for HF patients with LV systolic dysfunction,
      low LVEF, and prolonged QRS duration in sinus rhythm, since the vast majority of the CRT
      clinical research was performed in patients in sinus rhythm. However, in the ~25% of HF
      patients with permanent atrial fibrillation (AF), the effectiveness of CRT is not clear. It
      is therefore timely to address the question of whether the addition of CRT to optimal HF
      treatment, rate control and an ICD is beneficial to reduce all-cause mortality or HF
      hospitalization in HF patients in permanent AF with LV systolic dysfunction and prolonged
      QRS duration

      Objectives: to determine whether cardiac resynchronization therapy will reduce all-cause
      mortality or hospitalization for heart failure in patients with permanent atrial
      fibrillation, mild to moderate heart failure, left ventricular systolic dysfunction, and
      prolonged QRS duration, when compared to implantable cardioverter defibrillator (ICD)
      therapy alone

      Methods: This is a multi-centre randomized controlled trial of two treatment groups. The
      patients, primary physicians and the heart failure caregivers will be blinded to the
      treatment allocation. The device follow-up caregivers will not be blinded. Patients with
      NYHA Class II and III HF symptoms, LVEF HF &lt;35%, permanent AF, on optimal medical therapy
      and QRS durations ≥ 130 ms when the QRS morphology is LBBB, or QRS durations ≥ 150 ms when
      the QRS morphology is non-LBBB will be included in the trial. Patients should be suitable
      candidates for either of the 2 treatment strategies. There will be 950 patients randomized
      in 1:1 ratio to two groups: 1) ICD-CRT, 2) ICD only. All patients will undergo baseline
      clinical evaluation, quality of life assessment, medication assessment, blood chemistry
      including liver, renal, thyroid, and NT-proBNP. The patients will be followed at 1 month, 3
      months, 6 months and then every 6 months. A history and physical examination will be
      performed at baseline and at follow-up visits. Blood work, quality of life assessment, and
      6-minute walk distance will also be performed at baseline and at follow-up visits. The
      Investigators anticipate that this study will have a major impact on how HF patients in
      permanent AF with LV systolic dysfunction and prolonged QRS duration will be treated in the
      future.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>all-cause mortality</measure>
    <time_frame>41/2 year study</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>hospitalization for HF</measure>
    <time_frame>41/2 year study</time_frame>
    <safety_issue>No</safety_issue>
    <description>Primary outcome is composite of all cause mortality and hospitalization for heart failure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>cardiovascular mortality</measure>
    <time_frame>41/2 year study</time_frame>
    <safety_issue>No</safety_issue>
    <description>interim analysis is planned when 33% of patients enrolled have been followed for a minimum of 18 months. A final analysis will be performed at the conclusion of the trial.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>All-cause hospitalization</measure>
    <time_frame>41/2 year study</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">950</enrollment>
  <condition>Heart Disease</condition>
  <condition>Congestive Heart Failure</condition>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Optimal Medical therapy plus ICD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomized to the (ICD) Implantable-Defibrillator-Cardioverter only group will receive an ICD + optimal medical therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Optimal Medical therapy plus CRT/ICD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomized to the (ICD) Implantable-Defibrillator-Cardioverter plus cardiac resynchronisation therapy (CRT) group will receive an ICD + CRT and optimal medical therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Optimal Medical therapy plus ICD</intervention_name>
    <arm_group_label>Optimal Medical therapy plus ICD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Optimal Medical therapy plus CRT/ICD</intervention_name>
    <arm_group_label>Optimal Medical therapy plus CRT/ICD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with NYHA Class II or III HF symptoms

          -  Permanent AF

          -  Optimal Medical Therapy for HF of at least 3 months

          -  LVEF &lt; 35%

          -  Candidacy for an ICD for primary or secondary prevention of sudden cardiac death

          -  QRS durations ≥ 130 ms when the QRS morphology is LBBB, or QRS durations ≥

               -  150 ms when the QRS morphology is non-LBBB

        Exclusion Criteria:

          -  In-hospital patients who have acute cardiac or non-cardiac illness that     requires
             intensive care

          -  Intra-venous inotropic agent in the last 4 days

          -  Patients with a life expectancy of less than one year from non-cardiac cause.

          -  Expected to undergo cardiac transplantation within one year (status I)

          -  Acute coronary syndrome (including MI) &lt; 4 weeks

          -  Unable or unwilling to provide informed consent

          -  Uncorrected or uncorrectable primary valvular disease

          -  Restrictive, hypertrophic or reversible form of cardiomyopathy

          -  Severe primary pulmonary disease such as cor pulmonale

          -  Tricuspid prosthetic valve

          -  Patients included in other clinical trial that will affect the

          -  Coronary revascularization (CABG or PCI) &lt; 3 months

          -  Patients with an existing ICD or pacemaker
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony SL Tang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Ottawa Heart Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anthony SL Tang, MD</last_name>
    <phone>519-663-3746</phone>
    <email>anthonysltang@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>George A Wells, PhD</last_name>
    <phone>613-761-8640</phone>
    <email>GAWells@ottawaheart.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Libin Cardiovascular Institute of Alberta</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Steven Wilton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Alexandra Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Evan Lockwood, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mazankowski Alberta Heart Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Roopinder Sandhu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Columbian Hospital</name>
      <address>
        <city>New Westminster</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>John LeMaitre, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vancouver General Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Matthew Bennett, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Victoria Cardiac Arrhythmia Trials</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8R 4R2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Novak, MD</last_name>
      <phone>250-595-0400</phone>
    </contact>
    <investigator>
      <last_name>Paul Novak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Boniface General Hospital</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Colette Seifer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint John Regional Hospital</name>
      <address>
        <city>Saint John</city>
        <state>New Brunswick</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Satish Toal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Hospital</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Sean Connors, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth II Health Science</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Ratika Parkash, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hamilton Health Sciences</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jeff Healey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kingston General Hospital</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Damian Redfearn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Raymond Yee, MD</last_name>
      <phone>519-663-3746</phone>
      <email>ryee@uwo.ca</email>
    </contact>
    <investigator>
      <last_name>Peter Leong-Sit, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southlake Regional Health Centre</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Bernice Tsang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Ottawa Heart Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1W 4W7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David H Birnie, MD</last_name>
      <phone>613-761-4705</phone>
      <email>dbirnie@ottawaheart.ca</email>
    </contact>
    <investigator>
      <last_name>David H. Birnie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Michael's General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Arnold Pinter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital,</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Andrew Ha, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Eugene Crystal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montreal Heart Institute</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Bernard Thibault, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McGill Health Science Centre</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Vidal Essebag, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHUM Centre hospitalier universitaire de Montréal</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Benoit Coutu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital du Sacré-Cœur de Montréal</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Marcio Sturmer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut universitaire de cardiologie et de pneumologie de Quebec</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>François Philippon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Le Centre hospitalier universitaire de Sherbrooke</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Felix Ayala-Paredes, MD</last_name>
      <email>felix.ayala-paredes@usherbrooke.ca</email>
    </contact>
    <investigator>
      <last_name>Felix Ayala-Paredes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Regina General Hospital</name>
      <address>
        <city>Regina</city>
        <state>Saskatchewan</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Omar Sultan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Tang AS, Wells GA, Talajic M, Arnold MO, Sheldon R, Connolly S, Hohnloser SH, Nichol G, Birnie DH, Sapp JL, Yee R, Healey JS, Rouleau JL; Resynchronization-Defibrillation for Ambulatory Heart Failure Trial Investigators. Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med. 2010 Dec 16;363(25):2385-95. doi: 10.1056/NEJMoa1009540. Epub 2010 Nov 14.</citation>
    <PMID>21073365</PMID>
  </reference>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 20, 2013</lastchanged_date>
  <firstreceived_date>November 8, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>defibrillator</keyword>
  <keyword>cardiac resynchronization</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
